Imatinib

Imatinib binds to the ATP‑binding site of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, blocking their enzymatic activity. This inhibition stops downstream signaling pathways that promote malignant cell proliferation, survival and angiogenesis, leading to reduced tumor growth and increased cancer cell death.

The dose of Imatinib is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and concomitant medications. Only a qualified healthcare professional should determine the appropriate regimen.

Safety data for Imatinib in pregnancy and lactation are limited, and the drug may pose risks to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential benefits and risks with their oncologist before starting or continuing therapy.

To request Imatinib, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib was the first targeted tyrosine‑kinase inhibitor approved for chronic myeloid leukemia and remains a standard first‑line option. Newer agents such as dasatinib and nilotinib have broader kinase inhibition profiles and may be used when resistance or intolerance to Imatinib occurs, but Imatinib’s long‑term safety record makes it a widely accepted choice.

Imatinib tablets should be stored at ambient temperature below 25 °C, protected from moisture and light. Keep the medication in its original packaging until use and avoid storing it in bathrooms or near heat sources to maintain product stability.

Imatinib is taken orally as a tablet, usually with a glass of water. It can be taken with or without food, but patients should follow their physician’s instructions regarding timing and any dietary restrictions to ensure consistent absorption.

Serious risks include severe neutropenia or thrombocytopenia, hepatotoxicity, cardiac dysfunction, pulmonary hypertension, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for these events, and any concerning symptoms should prompt immediate medical evaluation.

Imatinib is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is also advised for patients with severe hepatic impairment, uncontrolled cardiac disease, or those taking medications that strongly interact with CYP3A4 without appropriate monitoring.